For the quarter ending 2025-09-30, GMED had $142,323K increase in cash & cash equivalents over the period. $213,878K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | 118,966 | 278,308 |
| Bargain purchase gain | 3,800 | 110,561 |
| Depreciation and amortization | 71,126 | 136,705 |
| Amortization of premiums on marketable securities | 53 | 421 |
| Provision for excess and obsolete inventory | 5,055 | 10,933 |
| Amortization of inventory fair value step-up | 6,958 | 6,015 |
| Amortization of 2025 notes fair value step-up | 0 | 6,658 |
| Stock-based compensation expense | 11,538 | 26,823 |
| Allowance for expected credit losses | 757 | 4,554 |
| Change in fair value of business acquisition liabilities | -2,721 | 5,389 |
| Change in deferred income taxes | 41,761 | -41,236 |
| (gain)/loss on disposal of assets, net | -2,307 | -6,131 |
| Payment of business acquisition-related liabilities | 661 | 15,764 |
| Net (gain)/loss from foreign currency adjustment | 3,279 | 11,342 |
| Accounts receivable | 8,424 | -20,395 |
| Inventories | 5,698 | 11,722 |
| Prepaid expenses and other assets | 7,541 | -852 |
| Accounts payable | 3,431 | -4,085 |
| Accrued expenses and other liabilities | 39,283 | -13,841 |
| Income taxes payable/receivable | -19,310 | -38,626 |
| Net cash provided by/(used in) operating activities | 249,695 | 255,165 |
| Purchases of marketable securities | 35,359 | 1,750 |
| Maturities of marketable securities | 0 | 58,630 |
| Repayments of borrowings from credit facility | - | 20,000 |
| Proceeds from credit facility | - | 20,000 |
| Sales of marketable securities | 0 | 115,608 |
| Purchases of property and equipment | 35,817 | 82,665 |
| Acquisition of businesses, net of cash acquired and purchases of intangible and other assets | 0 | 252,546 |
| Acquisition of intangible assets | 4,666 | 5,000 |
| Proceeds from credit facility | 20,000 | - |
| Repayments of borrowings from credit facility | 20,000 | - |
| Net cash provided by/(used in) investing activities | -75,842 | -167,723 |
| Payment of business acquisition-related liabilities | 3,376 | 7,864 |
| Net proceeds from exercise of stock options | 11,079 | 15,920 |
| Payments related to tax withholdings for share-based compensation | -255 | 2,953 |
| Repurchase of common stock | 40,000 | 215,451 |
| Repayment of senior convertible notes | 0 | 449,985 |
| Net cash provided by/(used in) financing activities | -32,042 | -660,333 |
| Effect of foreign exchange rates on cash | 512 | 17,899 |
| Net increase/(decrease) in cash and cash equivalents | 142,323 | -554,992 |
| Cash and cash equivalents at beginning of period | 784,438 | - |
| Cash and cash equivalents at end of period | 371,769 | - |
GLOBUS MEDICAL INC (GMED)
GLOBUS MEDICAL INC (GMED)